

Study Number: I11054

Test Type: TOX

Route: Oral Gavage

Species/Strain: Mouse/B6C3F1/N

C Number:

I11054

Study Gender:

Female

PWG Approval Date

See web page for date of PWG Approval

I04G: Mean Body Weight Gain

Test Compound: Sulfolane

CAS Number: 126-33-0

Date Report Requested: 02/27/2019

Time Report Requested: 10:54:36

Lab: Burleson Research Technologies

Study Number: I11054
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

I04G: Mean Body Weight Gain
Test Compound: Sulfolane
CAS Number: 126-33-0

Date Report Requested: 02/27/2019
Time Report Requested: 10:54:36
Lab: Burlinson Research Technologies

Females: Immunopath

Phase	Litter ID	Days	Treatment Groups (mg/kg)									
			0		1		10		30		100	
			Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD		0 - 6	0.8 ± 0.3	8	0.8 ± 0.1	8	1.3 ± 0.2	8	0.6 ± 0.1	8	0.6 ± 0.3	8
		6 - 13	0.5 ± 0.2	8	0.6 ± 0.2	8	0.7 ± 0.2	8	0.6 ± 0.2	8	0.4 ± 0.3	8
		13 - 20	0.5 ± 0.2	8	0.9 ± 0.2	8	0.4 ± 0.1	8	0.5 ± 0.1	8	0.5 ± 0.2	8
		20 - 27	1.2 ± 0.2	8	0.6 ± 0.3	8	0.9 ± 0.2	8	1.0 ± 0.2	8	1.0 ± 0.2	8
		27 - 34	0.4 ± 0.2	8	0.4 ± 0.2	8	0.6 ± 0.2	8	0.8 ± 0.3	8	0.4 ± 0.3	8
		34 - 41	0.4 ± 0.4	8	1.1 ± 0.3	8	0.9 ± 0.2	8	0.9 ± 0.3	8	0.9 ± 0.2	8
		41 - 48	0.9 ± 0.2	8	0.5 ± 0.4	8	1.0 ± 0.3	8	0.9 ± 0.2	8	1.0 ± 0.3	8
		48 - 55	1.2 ± 0.2	8	0.6 ± 0.4	8	0.8 ± 0.2	8	1.4 ± 0.3	8	0.6 ± 0.4	8
		55 - 62	0.6 ± 0.3	8	0.7 ± 0.3	8	0.6 ± 0.1	8	1.0 ± 0.3	8	0.6 ± 0.4	8
		62 - 69	0.4 ± 0.4	8	0.9 ± 0.2	8	0.9 ± 0.1	8	0.7 ± 0.2	8	0.8 ± 0.3	8
		69 - 76	0.5 ± 0.3	8	0.7 ± 0.3	8	0.7 ± 0.4	8	1.0 ± 0.2	8	1.3 ± 0.2	8
		76 - 83	1.0 ± 0.4	8	0.9 ± 0.4	8	0.5 ± 0.4	8	0.8 ± 0.2	8	1.1 ± 0.1	8
		83 - 90	-0.1 ± 0.2	8	-0.6 ± 0.4	8	0.4 ± 0.2	8	-0.4 ± 0.3	8	0.1 ± 0.6	8
	0 - 90	8.2 ± 1.0	8	8.1 ± 1.0	8	9.6 ± 1.1	8	9.8 ± 1.5	8	9.4 ± 1.1	8	

Study Number: I11054
Test Type: TOX
Route: Oral Gavage
Species/Strain: Mouse/B6C3F1/N

I04G: Mean Body Weight Gain
Test Compound: Sulfolane
CAS Number: 126-33-0

Date Report Requested: 02/27/2019
Time Report Requested: 10:54:36
Lab: Burleson Research Technologies

Females: Immunopath

Phase	Litter ID	Days	Treatment Groups (mg/kg)			
			300		50 mg/kg CPS	
			Wt Gain (g)	N	Wt Gain (g)	N
SD		0 - 6	0.4 ± 0.1	8	0.5 ± 0.1	8
		6 - 13	1.0 ± 0.2	8	0.7 ± 0.1	8
		13 - 20	0.6 ± 0.2	8	0.9 ± 0.2	8
		20 - 27	0.9 ± 0.1	8	0.9 ± 0.1	8
		27 - 34	0.6 ± 0.1	8	0.3 ± 0.3	8
		34 - 41	0.7 ± 0.3	8	0.6 ± 0.1	8
		41 - 48	0.7 ± 0.3	8	1.1 ± 0.3	8
		48 - 55	0.8 ± 0.3	8	0.8 ± 0.3	8
		55 - 62	0.8 ± 0.1	8	1.0 ± 0.3	8
		62 - 69	0.9 ± 0.2	8	1.1 ± 0.4	8
		69 - 76	1.0 ± 0.4	8	1.6 ± 0.4	8
		76 - 83	1.2 ± 0.3	8	0.2 ± 0.6	8
		83 - 90	0.2 ± 0.5	8	-0.7 ± 0.2	8
		0 - 90	9.8 ± 1.0	8	8.9 ± 1.2	8

Study Number: I11054

Test Type: TOX

Route: Oral Gavage

Species/Strain: Mouse/B6C3F1/N

I04G: Mean Body Weight Gain

Test Compound: Sulfolane

CAS Number: 126-33-0

Date Report Requested: 02/27/2019

Time Report Requested: 10:54:36

Lab: Burleson Research Technologies

LEGEND

Data are displayed as mean \pm SEM

SD – Study Day

Statistical analysis of weight data performed by Jonckheere (trend) and Williams or Dunnett (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the t-Test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

CPS = Cyclophosphamide

**** END OF REPORT ****